SCHEMBL22995188

SCHEMBL22995188

COC(=O)c1ccccc1OC(O)Oc1ccccc1C(=O)OC

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A3 Q01959 4/20 0.57
TSHR P16473 2/20 0.53
LMNA P02545 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
HSD17B10 Q99714 3/20 0.52
ALDH1A1 P00352 1/20 0.52
CFTR P13569 1/20 0.52
SLC6A4 P31645 3/20 0.51
KMT2A Q03164 3/20 0.50
KDM4E B2RXH2 2/20 0.50
HTT P42858 1/20 0.50
POLB P06746 1/20 0.50
ATM Q13315 1/20 0.50
MAPT P10636 2/20 0.49
GAA P10253 1/20 0.49
MAPK1 P28482 1/20 0.49
IRAK4 Q9NWZ3 1/20 0.47
HPGD P15428 1/20 0.47
MEN1 O00255 1/20 0.47
SLC6A2 P23975 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6280137 0.87 SLC6A3 (0.56) SLC6A3TSHRLMNAL3MBTL1HSD17B10
SCHEMBL4326100 0.87 SLC6A3 (0.56) SLC6A3TSHRLMNAL3MBTL1HSD17B10
SCHEMBL4036585 0.85 IRAK4 (0.66) SLC6A3TSHRLMNAL3MBTL1HSD17B10
SCHEMBL1856862 0.84 SLC6A3 (0.56) SLC6A3TSHRLMNAL3MBTL1HSD17B10
SCHEMBL3791612 0.81 SLC6A3 (0.53) SLC6A3TSHRLMNAL3MBTL1HSD17B10
Methyl 2-Methoxybenzoate SCHEMBL29702077 0.80 TSHR (0.69) SLC6A3TSHRLMNAL3MBTL1HSD17B10
SCHEMBL2441955 0.80 SLC6A3 (0.65) SLC6A3TSHRLMNAL3MBTL1HSD17B10
Methyl 2-Methoxybenzoate SCHEMBL196037 0.80 TSHR (0.69) SLC6A3TSHRLMNAL3MBTL1HSD17B10
SCHEMBL9774322 0.80 SLC6A3 (0.55) SLC6A3TSHRLMNAL3MBTL1HSD17B10
SCHEMBL4393207 0.79 HSD17B10 (0.73) SLC6A3TSHRLMNAL3MBTL1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021028806-A1 HETEROCYCLIC WDR5 INHIBITORS AS ANTI-CANCER COMPOUNDS NOVARTIS AG (CH) 2021-02-18 WO disclosed